Abstract
The clinical applicability of new therapies may be exaggerated bythe Hawthorne effect of clinical trials. The European Safe Implemen-tation of Thrombolysis in Stroke Monitoring Study (SITS-MOST)registry — a mandated requirement of European drug licensingauthorities — was established to monitor thrombolysis in day-to-dayclinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
